{"DataElement":{"publicId":"4743100","version":"1","preferredName":"Treatment Cohort Study 9149 Cohort Code","preferredDefinition":"The code that represents the information pertaining to protocol 9149 in which subsets of a defined population are identified.","longName":"TX_COH_SDY_9149_CD","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2497526","version":"1","preferredName":"Treatment Cohort Study","preferredDefinition":"Information pertaining to studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"TX_COHORT_STDY","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"2416951","version":"1","preferredName":"Therapy","preferredDefinition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"02DBEE3F-243E-103A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-12","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-12","modifiedBy":"ONEDATA","dateModified":"2005-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2497524","version":"1","preferredName":"Cohort Study","preferredDefinition":"Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.","longName":"C15208","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort Study","conceptCode":"C15208","definition":"A research study that compares a particular outcome (such as lung cancer) in groups of individuals who are alike in many ways but differ by a certain characteristic (for example, female nurses who smoke compared with those who do not smoke).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FC9E-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"ONEDATA","dateModified":"2006-07-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"191BBE49-FCAF-4C77-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-21","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-07-21","modifiedBy":"SOKKERL","dateModified":"2017-05-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4743091","version":"1","preferredName":"9149 Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic._A system of numbered categories for representation of data.","longName":"4743091v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"ARM B TAC4","valueDescription":"ARM B TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","ValueMeaning":{"publicId":"4743092","version":"1","preferredName":"ARM B TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","longName":"4743092","preferredDefinition":"ARM B TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2CC3-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2CDC-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM B TAC3","valueDescription":"ARM B TAC3: Trametinib 2mg PO QD","ValueMeaning":{"publicId":"4743093","version":"1","preferredName":"ARM B TAC3: Trametinib 2mg PO QD","longName":"4743093","preferredDefinition":"ARM B TAC3: Trametinib 2mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2CE6-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2CFF-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM B TAC2","valueDescription":"ARM B TAC2: Everolimus 10 mg PO QD","ValueMeaning":{"publicId":"4743094","version":"1","preferredName":"ARM B TAC2: Everolimus 10 mg PO QD","longName":"4743094","preferredDefinition":"ARM B TAC2: Everolimus 10 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2D09-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2D22-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM B TAC1","valueDescription":"ARM B TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","ValueMeaning":{"publicId":"4743095","version":"1","preferredName":"ARM B TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","longName":"4743095","preferredDefinition":"ARM B TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2D2C-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2D45-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM A TAC4","valueDescription":"ARM A TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","ValueMeaning":{"publicId":"4743096","version":"1","preferredName":"ARM A TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","longName":"4743096","preferredDefinition":"ARM A TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2D4F-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2D68-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM A TAC3","valueDescription":"ARM A TAC3 Trametinib 2mg PO QD","ValueMeaning":{"publicId":"4743097","version":"1","preferredName":"ARM A TAC3 Trametinib 2mg PO QD","longName":"4743097","preferredDefinition":"ARM A TAC3 Trametinib 2mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2D72-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2D8B-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM A TAC2","valueDescription":"ARM A TAC2: Everolimus 10 mg PO QD","ValueMeaning":{"publicId":"4743098","version":"1","preferredName":"ARM A TAC2: Everolimus 10 mg PO QD","longName":"4743098","preferredDefinition":"ARM A TAC2: Everolimus 10 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2D95-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2DAE-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"ARM A TAC1","valueDescription":"ARM A TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","ValueMeaning":{"publicId":"4743099","version":"1","preferredName":"ARM A TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","longName":"4743099","preferredDefinition":"ARM A TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2DB8-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"10F8B816-2DD1-720A-E050-BB89AD434655","beginDate":"2015-03-10","endDate":"2016-01-11","createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"TAC-0","valueDescription":"TAC-0: Signed Informed Consent and prior to intervention","ValueMeaning":{"publicId":"5098573","version":"1","preferredName":"TAC-0: Signed Informed Consent and prior to intervention","longName":"5098573","preferredDefinition":"TAC-0","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"29127CE8-F2CB-0F1B-E050-BB89AD4357A9","latestVersionIndicator":"Yes","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"29127CE8-F2E4-0F1B-E050-BB89AD4357A9","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-01-11","modifiedBy":"ONEDATA","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"PENDING ASSIGNMENT","valueDescription":"Pending Assignment","ValueMeaning":{"publicId":"4983478","version":"1","preferredName":"Pending Assignment","longName":"4983478","preferredDefinition":"Not yet decided or settled; awaiting conclusion or confirmation.: An allotting or an appointment to a particular person or use, or for a particular time or object.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pending","conceptCode":"C53470","definition":"Not yet decided or settled; awaiting conclusion or confirmation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assignment","conceptCode":"C25426","definition":"An allotting or an appointment to a particular person or use, or for a particular time or object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1E2629DD-5357-838D-E050-BB89AD430258","latestVersionIndicator":"Yes","beginDate":"2015-08-25","endDate":null,"createdBy":"TAYLORT","dateCreated":"2015-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1E2629DD-5370-838D-E050-BB89AD430258","beginDate":"2015-08-25","endDate":"2016-01-11","createdBy":"TAYLORT","dateCreated":"2015-08-25","modifiedBy":"MAESKEB","dateModified":"2016-01-11","deletedIndicator":"No"},{"value":"TAC1","valueDescription":"TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","ValueMeaning":{"publicId":"5153293","version":"1","preferredName":"TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","longName":"5153293","preferredDefinition":"TAC1: ABT-888 40mg PO BID on days 1-7; Temozolomide 150 mg/m2 PO QD on days 1-5","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA54A2E-A60E-D772-E050-BB89AD432E6E","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA54A2E-A627-D772-E050-BB89AD432E6E","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"},{"value":"TAC2","valueDescription":"TAC2: Everolimus 10 mg PO QD","ValueMeaning":{"publicId":"5153294","version":"1","preferredName":"TAC2: Everolimus 10 mg PO QD","longName":"5153294","preferredDefinition":"TAC2: Everolimus 10 mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA54A2E-A631-D772-E050-BB89AD432E6E","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA54A2E-A64A-D772-E050-BB89AD432E6E","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"},{"value":"TAC3","valueDescription":"TAC3: Trametinib 2mg PO QD","ValueMeaning":{"publicId":"5153295","version":"1","preferredName":"TAC3: Trametinib 2mg PO QD","longName":"5153295","preferredDefinition":"TAC3: Trametinib 2mg PO QD","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA54A2E-A654-D772-E050-BB89AD432E6E","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA54A2E-A66D-D772-E050-BB89AD432E6E","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"},{"value":"TAC4","valueDescription":"TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","ValueMeaning":{"publicId":"5153296","version":"1","preferredName":"TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","longName":"5153296","preferredDefinition":"TAC4: MK-1775 225 mg PO BID x 5 doses on days 1-3; Carboplatin AUC 5 IV over 30 min on day 1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DA54A2E-A677-D772-E050-BB89AD432E6E","latestVersionIndicator":"Yes","beginDate":"2016-03-09","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2DA54A2E-A690-D772-E050-BB89AD432E6E","beginDate":"2016-01-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2016-03-09","modifiedBy":"ONEDATA","dateModified":"2016-03-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"4386398","version":"1","preferredName":"Cohort Code","preferredDefinition":"A group of individuals, identified by a common characteristic.:A system of numbered categories for representation of data.","longName":"C61512:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cohort","conceptCode":"C61512","definition":"A group of individuals, identified by a common characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE558C16-1C27-C6A8-E040-BB89AD430BEE","latestVersionIndicator":"Yes","beginDate":"2014-07-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2014-07-16","modifiedBy":"ONEDATA","dateModified":"2014-07-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2CAD-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"HARTLEYG","dateModified":"2016-03-24","changeDescription":"8/25/15 Removed 'Pending'; Added Pending Assignment. tt_ 9149_Theradex_03.10.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Please select the cohort:","type":"Preferred Question Text","description":"Please select the cohort:","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"10F8B816-2DDB-720A-E050-BB89AD434655","latestVersionIndicator":"Yes","beginDate":"2015-03-10","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2015-03-10","modifiedBy":"HARTLEYG","dateModified":"2015-03-11","changeDescription":"9149_Theradex_03.10.15_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}